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ORIGINAL ARTICLE – THORACIC ONCOLOGY
Prognostic Value of the Circumferential Resection Margin
in Esophageal Cancer Patients After Neoadjuvant
Chemoradiotherapy
J. B. Hulshoff, BSc1, Z. Faiz, MD1, A. Karrenbeld, MD2, G. Kats-Ugurlu, MD2, J. G. M. Burgerhof, MSc3,
J. K. Smit, MD, PhD1, and J. Th. M. Plukker, MD, PhD1
1Department of Surgical Oncology, University of Groningen, University Medical Center Groningen, Groningen, The
Netherlands; 2Department of Pathology, University of Groningen, University Medical Center Groningen, Groningen, The
Netherlands; 3Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen,
The Netherlands
ABSTRACT
Background. Circumferential resection margins (CRM)
for esophageal cancer (EC), defined by the College of
American Pathologists (CAP; [0 mm) or the Royal Col-
lege of Pathologists (RCP;[1 mm) as tumor-free (R0), are
based on a surgery-alone approach. We evaluated the
usefulness of both definitions in current practice with
neoadjuvant chemoradiotherapy (nCRT).
Methods. CRMs were measured in 209 patients (104 with
nCRT) with locally advanced EC after transthoracic
esophagectomy. Local recurrence and cancer related death
were scored as events. Patients were followed for at least
2 years or until death. Prognostic factors (P\ 0.1 in uni-
variate analyses) for 2-year disease-free survival (DFS) and
local recurrence-free survival (LRFS) were incorporated in
multivariate Cox regression analyses. Both CRM mea-
surements were analyzed separately and prognostic cutoff
values (0–1.0 mm) were assessed in both groups.
Results. Independent prognostic factors (P\ 0.05) for 2-
year DFS were tumor length, lymph node ratio, angioin-
vasion, and CAP R0 in the surgery-alone group and pN
stage (P\ 0.01) in the nCRT group. Prognostic factors
(P\ 0.05) for 2-year LRFS were CAP, lymph node ratio,
and tumor length in the surgery-alone group, and CAP and
grade in the nCRT group. Optimal CRM cutoff values
between 0.0 and 0.2 mm were prognostic for 2-year DFS in
the surgery-alone and at 0.3 mm for the nCRT group.
Conclusions. nCRT affected the CRM cutoff values. After
nCRT, the CRM R0 according to the CAP was only
prognostic for 2-year LRFS. However, in the surgery-alone
group, it was prognostic for both the 2-year DFS and
LRFS.
Even with neoadjuvant chemoradiotherapy (nCRT), the
overall 5-year survival rate after esophagectomy remains
relatively low at 47 % in patients with locally advanced
esophageal cancer (EC).1 A strong prognostic indicator
after a curative intended esophagectomy is the circumfer-
ential resection margin (CRM), rendered as microscopic
tumor-free (R0) or tumor-positive (R1).2–8 Commonly used
definitions of a circumferentially R0 resection are those of
the College of American Pathologist (CAP; CRM[0 mm)
and the Royal College of Pathologists (RCP; CRM
[1 mm).9,10 After nCRT, the optimal CRM may be
influenced by tumor downsizing, which facilitates a R0
resection.1
The optimal CRM cutoff point after nCRT has not been
defined yet. Recently, two meta-analyses showed a sig-
nificant association of a positive CRM according to both
definitions with poor outcome, which was even worse in
patients with stage T3 disease or after nCRT.11,12 However,
these studies did not assess which CRM definition was
more powerful after nCRT, while contradictory results
after nCRT were reported in three other studies without a
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surgery-alone control group.13–15 Two studies, with only
squamous cell carcinoma, showed a significant better sur-
vival rate in patients with a CRM[ 1 mm, whereas no
survival benefit was observed in R0 resections according to
the CAP and RCP in a study with only T3 stage
adenocarcinomas.13–15
We assessed the optimal CRM cutoff point and the
prognostic value of R0 resections according to the CAP
and RCP criteria in EC patients treated either with nCRT or
surgery alone.
PATIENTS AND METHODS
Data collection of this explorative retrospective study
was provided from a prospective maintained database of
EC patients according to the national guidelines and the
rules approved by the local ethical commission (www.
ccmo.nl). We included only patients with a locally
advanced curatively resectable EC (stage II-III) treated
between 1997 and 2013, in whom the CRM was adequately
assessed by our expert pathologists. Of the patients treated
with nCRT (n = 127) between 2005 and 2013, 23 were
excluded because of the following criteria: incomplete
medical records (n = 0), postoperative mortality (death
within 90 days or in-hospital, n = 10), progressive disease
within 3 months after surgery or microscopic irradical (R1;
tumor cells \1 mm) longitudinal margins (n = 0) or fol-
low-up \24 months (n = 13). Based on these exclusion
criteria, a reference group of surgery-alone treated patients
(n = 105) was constructed. Patients and tumor-related
factors were matched and were equally distributed between
both groups (Table 1).
Tumors staged according to the 6th TNM edition were
recoded into the 7th edition.16,17 Before 2000 (n = 11),
staging consisted of endoscopic ultrasonography (EUS)
with fine-needle aspiration (FNA), computed tomography
(CT) of the neck, thorax, and abdomen and occasionally
18-F-fluorodeoxyglucose positron emission tomography
(FDG-PET, n = 8). After 2000, a standard FDG-PET was
added, which was replaced by FDG-PET/CT after 2009.
Two weeks after nCRT, patients were restaged with a CT
thorax and abdomen.
Treatment
All patients underwent a transthoracic esophagectomy
with en bloc dissection of regional mediastinal and
abdominal (including the celiac trunk region) lymph nodes.
Patients with nCRT were treated according to the Dutch
Chemoradiotherapy for Oesophageal Cancer Followed by
Surgery Study (CROSS) regimen, consisting of intravenous
paclitaxel (50 mg/m2) and carboplatin (AUC: 2 ml/min),
administered five times during a 5-week concurrent radia-
tion period (41.4 Gy/23 fractions of 1.8 Gy).1 Before 2009,
patients received nCRT based on their participation in the
CROSS trial, from 2009 onwards nCRT became standard
of care for locally advanced EC patients (T1-4aN1-3, T2-
4aN0-3; n = 75).
Pathology
Resected specimens were examined according to a
standardized protocol by two specialized gastrointestinal
pathologists. The resected specimen was pinned on a Sty-
rofoam plate by the surgeon, enabling accurate
pathological assessment of the marked Clinical Tumor
Volume and Gross Tumor Volume areas in patients treated
with nCRT.18 CRM was measured according to the method
of Quirke; the specimens were inked with Indian ink and
fixed in formalin during 24 h.6 The specimens were sliced
into transverse cross-sections of 0.5 cm for macroscopic
assessment and sampling of at least two sections with the
smallest CRM.2 The CRM was microscopically assessed
on hematoxylin and eosin stained samples in tenths of
millimetres. Furthermore, the pT-stage, pN-stage, the
lymph-node ratio ([0.2 metastatic lymph node ratio),
number of positive lymph nodes ([4), histological tumor
type, tumor grade, angioinvasion, and perineural tumor
growth were assessed.
Follow-up
Patients were followed for at least 2 years or until death,
every 3 months during the first year after surgery, every
6 months in the second year, and every year thereafter for
the next 10 years. Tumor recurrence was defined as
histo/cytologically proven, suspected radiological imaging,
or clinically evident recurrence. Local recurrence included
recurrent disease at the anastomotic site or in the original
tumor/mediastinal bed.
Statistical Analysis
Distribution of continuous patient characteristics was
reported as median [interquartile range] and categorical
variables were reported in numbers and percentages. The
patients groups were compared with the Mann–Whitney
test for continuous variables and v2 or Fisher exact test for
categorical response variables. Kaplan–Meier curves and
log-rank test determine the 5-year disease-free survival
(DFS) and local recurrence-free survival (LRFS) of both
CRM definitions. Prognostic values of all variables for 2-
year DFS were assessed with univariate Cox regression
analysis. Factors within the univariate analysis were: age,
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tumor type, and grade (G1–2 vs. G3–4), clinical T and N
stage, tumor length ([5 cm, measured endoscopic or with
CT), treatment type (nCRT or surgery alone), and patho-
logic outcome: T and N stage, number of LN metastases
([4), and metastatic lymph node ratio ([0.2), perineural
growth, and angioinvasion. Multivariate Cox regression
was performed by incorporating all variables with a P value
\0.1 on univariate analysis. Both, the CAP (CRM[0 mm)
TABLE 1 Patient characteristics in the surgery-alone and neoadjuvant chemoradiotherapy (nCRT) groups
nCRT (n = 104) Surgery alone (n = 105) P value
Male 79 (76.0 %) 82 (78.1 %) 0.714a
Age (year), median (IQR) 63 (56–67) 64 (57–69) 0.228b
Histology 0.382a
Adenocarcinoma 88 (84.6 %) 84 (80 %)
Squamous cell carcinoma 16 (15.4 %) 21 (20 %)
Tumor location 0.654a
Middle esophagus 8 (7.7 %) 12 (11.4 %)
Distal esophagus 50 (48.1 %) 49 (46.7 %)
GEJ 46 (44.2 %) 44 (41.9 %)
Tumor length[5 cm 59 (56.7 %) 60 (57.1 %) 0.695b
cT-stage 0.221a
T2 16 (15.4 %) 9 (8.6 %)
T3 83 (79.8 %) 93 (88.6 %)
T4a 5 (4.8 %) 3 (2.9 %)
cN-stage 0.176a
N0 27 (26 %) 41 (39 %)
N1 50 (48.1 %) 44 (41.9 %)
N2 22 (21.2 %) 18 (17.1 %)
N3 5 (4.8 %) 2 (1.9 %)
pT-stage \0.001c
Tx 1 (1 %)
T0 21 (20.2 %)
T1 22 (21.2 %)
T2 14 (13.5 %) 20 (19 %)
T3 46 (44.2 %) 82 (78.1 %)
T4a 0 (0 %) 3 (2.9 %)
pN-stage \0.001a
N0 62 (59.6 %) 28 (26.7 %)
N1 26 (25.0 %) 34 (32.4 %)
N2 11 (10.6 %) 25 (23.8 %)
N3 5 (4.8 %) 18 (17.1 %)
Perineural growth 22 (21.2 %) 33 (31.4 %) 0.084a
Angioinvasion 22 (21.2 %) 51 (48.6 %) \0.001a
Number of LN ([4 LN?) 10 (9.6 %) 32 (30.5 %) \0.001a
Lymph node ratio ([0.2) 18 (17.3 %) 50 (47.6 %) \0.001a
Follow-up mo, median (IQR) 27.5 (15.0–42.0) 29 (15.5–56.0) 0.241b
Tumor recurrence 63 (60.6 %) 75 (71.4 %) 0.098a
Local recurrence 17 (16.3 %) 35 (33.3 %) 0.005a
Death 60 (57.7 %) 83 (79 %) 0.001a
Tumor-related death 54 (51.9 %) 73 (69.5 %) 0.009a
CRM (mm), median (IQR) 3.3 (1.0–5.0) 0.5 (0–1.4) \0.001b
0 9 (8.7 %) 27 (25.7 %) \0.001a
0–1 13 (12.5 %) 40 (38.1 %) \0.001a
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and RCP (CRM[1 mm) definition entered the multivariate
analysis separately. The prognostic value of R0 resections
according to the RCP and CAP for the 2-year DFS and 2-
year LRFS was assessed with multivariate Cox regression
analyses in both treatment groups. To assess the optimal
cutoff value of the CRM on 2-year DFS, an explorative
analysis was performed in both groups. Univariate analyses
were undertaken to assess the prognostic value of all cutoff
values (from 0.0 to 1.0 mm). The observed interval is
based on the assumption that the expected optimal CRM
cutoff should be between 0.0 and 1.0 mm. The Akaike
Information Criterion (AIC), which quantifies the quality
of a statistical model for a set of data was used to indirectly
compare the prognostic value of the CAP and RCP
model.19 It penalizes the number of explanatory variables
by adding twice the number of variables in the model to the
-2 log likelihood; in a formula AIC = -2 log likelihood
?2 k, in which k is the number of explanatory variables in
the model. The model with the lowest AIC was considered
to be most prognostic. The backwards likelihood ratio
method was used in the Cox regression analysis. Analyses
were performed with SPSS version 22.
RESULTS
Patient characteristics are summarized in Table 1. All
nCRT patients with CAP-R1 resections (n = 9; 8.7 %) had
stage pT3. Of the 27 (25.7 %) R1 resections in patients
treated with surgery alone, 24 had stage pT3, 1 had pT2,
and 2 had stage pT4a disease. The median CRM differed
significantly with 3.3 [interquartile range (IQR) 1.0–5.0]
mm versus 0.5 (IQR 0–1.4) mm for the nCRT and surgery-
alone group, respectively. The median follow up was 29.0
(IQR 15.5–56.0) months and 27.5 (IQR 15.0–42.0) in the
surgery-alone and nCRT groups, respectively.
Prognostic Value of the CAP and RCP Criteria
Figure 1 displays the DFS of both treatment groups,
with a R0 resection or involved CRM (R1 resection)
according to CAP (Fig. 1a) and RCP (Fig. 1b). With the
log-rank test, the CAP definition was prognostic for 5-year
DFS in both the surgery (P = 0.008) and nCRT group
(P\ 0.001) and the RCP definition was prognostic in the
nCRT group (P\ 0.001) but not in the surgery group
(P = 0.071). The 5-year DFS was not different
(P = 0.131) between CAP R1 patients treated with or
without nCRT but differed (P = 0.031) between patients
with an RCP R1 resection in both groups.
Table 2 displays all prognostic factors with a P\ 0.1 on
univariate analysis and Table 3 shows the multivariate Cox
regression models containing either the CAP or RCP for 2-
year DFS and LRFS in both groups. Independent prog-
nostic factors for 2-year DFS in the surgery-alone group
were tumor length [P = 0.006, hazard ratio (HR) 2.68, CI
1.33–5.43], lymph node ratio (P = 0.047, HR 2.57, CI
1.01–6.51), and CAP (P = 0.012, HR 0.41, CI 0.21–0.83).
Independent prognostic factors for 2-year LRFS were
lymph node ratio (P = 0.020, HR 3.11, CI 1.20–8.09),
tumor length (P = 0.002, HR 10.99, CI 2.49–48.43), and
CAP (P = 0.004, HR 0.27, CI 0.11–0.658). Both for 2-year
DFS and LRFS, the model containing the CAP had a lower
AIC than the RCP model and therefore was more
prognostic.
The only independent prognostic factors for 2-year DFS
in the nCRT group was the pN-stage (overall P = 0.004),
pN1 (P = 0.007, HR 2.70, CI 1.31–5.59), and pN2–3
(P = 0.005, HR 3.39, CI 1.43–8.03). Both CAP
(P = 0.001, HR 0.06, CI 0.01–0.31) and tumor grade
(P = 0.008, HR 16.91, CI 2.12–135.05) were prognostic
for 2-year LRFS. For both 2-year DFS and LRFS, the
multivariate regression model containing the CAP defini-
tion had a lower AIC and therefore was more prognostic.
Optimal CRM after Surgery Alone and after nCRT
CRM cutoff values of 0.0 (P = 0.012, HR = 0.41, CI
0.21–0.83, AIC = 317.0), 0.1 (P = 0.045, HR = 0.50, CI
0.25–0.98, AIC = 320.0), and 0.2 mm (P = 0.028,
HR = 0.48, CI 0.25–0.92, AIC = 318.8) were independent
prognostic factors for 2-year DFS in the surgery-alone
group. Based on the AIC, the 0.0-mm cutoff value (CAP)
TABLE 1 continued
nCRT (n = 104) Surgery alone (n = 105) P value
[1 82 (78.8 %) 38 (36.2 %) \0.001a
nCRT neoadjuvant chemoradiotherapy, cT clinical T stage, cN clinical lymph node stage, pT pathological T stage, pN pathologic lymph node




c Fisher exact test
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was the most prognostic. However, in the nCRT group, the
optimal cutoff value for 2-year DFS was 0.3 mm
(P = 0.045, HR = 0.35, CI 0.13–0.98, AIC = 348.1).
DISCUSSION
The prognostic value of the circumferential margin
(CRM) has been proven in EC patients after surgery alone,
but its significance after neoadjuvant treatment is not well
defined yet. This study conducted in stage II-III EC patients
showed that both definitions of a free CRM were not
prognostic for 2-year DFS in patients treated with nCRT.
The CAP definition ([0 mm), however, was an indepen-
dent prognostic factor for 2-year DFS in the surgery-alone
group and for LRFS in the nCRT and surgery-alone group.
The optimal CRM cutoff value for 2-year DFS was 0.3 and
between 0.0 and 0.2 mm in the nCRT and surgery-alone
group, respectively.
This study is one of the first to assess the optimal cutoff
value of the CRM after nCRT; previously published studies
used either the RCP or CAP criteria of a free CRM.
Although neoadjuvant treatment decreases the rate of R1
resection by transversal and sagittal tumor reduction, the
induced fibrosis may contain different amounts of unde-
tectable viable tumor cells.1 Therefore, the CRM
assessment depends upon accurate histological examina-
tion of residual tumor, which might be related to tumor
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FIG. 1 Disease-free survival in
patients treated with neoadjuvant
chemoradiotherapy and surgery-alone,
with circumferential microscopic
tumor-free (R0) or involved resection
margins (R1), according to a CAP
(0 mm) and b RCP (1 mm)
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several studies reported conflicting results in patients
treated with nCRT (Table 4). Chao et al. described a sig-
nificantly better disease-free and disease-specific survival,
whereas Liu et al. noted a significantly better overall sur-
vival (OS).13,14 However, Harvin et al. failed to prove a
survival benefit after nCRT with respect to both CAP and
RCP–CRM resections.15 This difference might be
explained by the inclusion of different pathologic tumor
types; Harvin et al. only included ypT3 or higher adeno-
carcinomas, whereas Chao et al. and Liu et al. included
only patients with squamous cell carcinomas.13–15 In our
study, histologic tumor type did not to affect the prognostic
value of the CRMs for DFS and LRFS, although the
number of squamous cell carcinomas in the nCRT group
was rather small (n = 16). Inclusion of pathologic T3
tumors in determining the optimal CRM seems
TABLE 2 Prognostic factors with P\ 0.1 on univariate analysis for disease-free and local recurrence-free survival in the surgery-alone and
neoadjuvant chemoradiotherapy groups
Surgery-alone group
2-year DFS 2-year LRFS
HR 95 % CI P value HR 95 % CI P value
pN0 1.00 0.001a 1.00 0.007a
pN1 3.36 1.10–10.32 0.034 4.08 0.87–19.26 0.076
pN2 7.36 2.47–21.92 0.000 3.39 0.62–18.56 0.160
pN3 8.05 2.58–25.05 0.000 11.54 2.48–53.79 0.002
Tumor length 2.23 1.14–4.34 0.019 8.45 1.97–36.21 0.004
Perineural growth 2.00 1.11–3.60 0.021 NS
Angioinvasion 2.90 1.49–5.65 0.002 NS
Number of LN 4.01 2.21–7.26 \0.001 3.41 1.46–7.97 0.005
Lymph node ratio 3.96 2.08–7.55 \0.001 3.51 1.44–8.57 0.006
CAP R0 0.45 0.25–0.82 0.010 0.42 0.18–0.98 0.044
RCP R0 0.46 0.23–0.91 0.025 0.52 0.20–1.32 0.168
nCRT group
2-year DFS 2-year LRFS
HR 95 % CI P value HR 95 % CI P value
cT2 1.00 0.013a NS
cT3 5.13 1.24–21.22 0.024
cT4a 12.98 2.36–71.45 0.003
pT0 1.00 0.054a NS
pT1 1.13 0.36–3.49 0.837
pT2 1.83 0.61–5.44 0.279
pT3 2.74 1.13–6.64 0.025
pN0 1.00 \0.001a 1.00 0.047a
pN1 2.58 1.30–5.13 0.007 0.56 0.07–4.65 0.590
pN2 4.69 2.14–10.30 0.000 5.37 1.28–22.55 0.022
pN3 6.87 2.47–19.11 0.000 7.31 0.76–70.88 0.086
Perineural growth 1.87 0.97–3.38 0.062 NS
Angioinvasion 1.81 0.98–3.53 0.055 NS
Number of LN 3.90 1.90–7.98 \0.001 8.00 1.92–33.25 0.004
Lymph node ratio 2.78 1.48–5.20 0.001 4.31 1.25–14.95 0.021
CAP R0 0.28 0.13–0.61 0.001 0.42 0.18–0.98 \0.001
RCP R0 0.40 0.22–0.74 0.003 0.30 0.09–1.06 0.061
DFS disease-free survival, LRFS local recurrence free survival, CI confidence interval, cT clinical T stage, cN clinical lymph node stage, pT
pathological T stage, pN pathologic lymph node stage, LN lymph node, CRM circumferential resection margin, R0 tumor-free resection margin,
CAP College of American Pathologists, RCP Royal College of Pathologists, NS not significant
a Overall P value of the categorical variables
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comprehensible as circumferential R1 resections in pT2
tumors are generally considered to be caused by inadequate
surgery.7,20,21 Moreover, Rao et al. stated that CRM
involvement in the EC specimen is related to advanced
disease rather than being an indicator of completeness of
resection.4 In our study, only one patient staged as ypT2
disease had a R1 resection, due to extensive angioinvasive
tumor growth within the CRM, which depends more on
biologic aggressiveness rather than poor surgery. Another
factor that might influence the CRM is the used surgical
TABLE 3 Multivariate analysis of models containing the CRM definition according to the CAP (CRM 0 mm) or the RCP (CRM 1 mm), in the
surgery-alone and neoadjuvant chemoradiotherapy groups
Surgery-alone group
2-year DFS 2-year LRFS
HR 95 % CI P value HR 95 % CI P value
CAP model (AIC = 317.0) CAP model (AIC = 168.2)
CAP 0.41 0.21–0.83 0.012a CAP 0.27 0.11–0.658 0.004a
LN ratio 2.57 1.01–6.51 0.047a LN ratio 3.11 1.20–8.09 0.020a
Tumor length 2.68 1.33–5.43 0.006a Tumor length 10.99 2.49–48.43 0.002a
Angioinvasion 1.90 0.94–3.85 0.075
No. of LN? 2.13 0.92–4.95 0.078
RCP model (AIC = 320.9) RCP model (AIC = 174.2)
RCP 0.83 0.38–1.78 0.627 RCP 0.57 0.22–1.51 0.258
LN ratio 2.68 1.05–6.81 0.039a LN ratio 3.13 1.12–8.24 0.021a
Angioinvasion 1.95 0.94–4.03 0.072
Perineural growth 1.89 0.99–3.59 0.053
Tumor length 2.52 1.25–5.09 0.010a Tumor length 8.59 1.99–37.08 0.004a
No. of LN 1.92 0.84–4.39 0.123
nCRT group
2-year DFS 2-year LR
HR 95 % CI P value HR 95 % CI P value
CAP model (AIC = 349.9) CAP model (AIC = 73.5)
CAP 0.47 0.18–1.23 0.124 CAP 0.06 0.01–0.31 0.001a
cT 3.20 0.76–13.49 0.114
pN0 1.00 0.004a,b Grade 16.91 2.12–135.05 0.008a
pN1 2.70 1.31–5.59 0.007
pN2-3 3.39 1.43–8.03 0.005
RCP model (AIC = 350.3) RCP model (AIC = 80.0)
RCP 0.69 0.31–1.52 0.359 RCP 1.01 0.08–13.50 0.995
cT 1.00 0.275 pN0–1 1.00 0.203
pN1–2 8.81 0.31–252.232.32 0.51–10.51
pN0 1.00 0.014a,b Grade 30.07 2.79–324.60 0.005a
pN1 2.51 1.22–5.21 0.014 No. of LN 0.73 0.06–8.94 0.804
pN2–3 2.99 1.23–7.32 0.016
pT0–1 1.00 0.359b LN ratio 2.60 0.44–15.42 0.294
pT2 1.96 0.70–5.49 0.202
pT3–4a 1.84 0.71–4.73 0.209
DFS disease-free survival, LRFS local recurrence-free survival, CI confidence interval, SCC squamous cell carcinoma, cT clinical T stage, cN
clinical lymph node stage, pT pathological T stage, pN pathologic lymph node stage, LN lymph node, CRM circumferential margin, R0 tumor-
free resection margin, CAP College of American Pathologists, RCP Royal College of Pathologists
a Significant (P\ 0.05)
b Overall P value of the categorical variables
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method; Suttie et al. noted that the transhiatal approach
resulted in significantly more CRM involvement compared
with the transthoracic approach.22 Because the transtho-
racic approach is our standard method, we could disregard
this potential confounding effect.
Three other studies assessed the value of the CRM in
which only a part of the included patients received nCRT,
again with conflicting results.23–25 Thompson et al.
(n = 240, 52 % nCRT) did not find a survival benefit,
whereas Reid et al. (n = 269, 15,6 % nCRT) found a
significantly better DFS and OS in patients with a RCP R0
resection.23,25 Farrell et al. (n = 157, 52 % nCRT) found
the CAP definition (P = 0.02) more prognostic for the OS
than the RCP definition.24
As in patients treated with nCRT, the optimal CRM
definition in surgically treated patients also is unclear. Two
recent meta-analyses showed that both CRM definitions
were associated with a poor survival, although the CAP
criteria differentiated higher-risk groups.11,12 Moreover
Chan et al. found that the CAP definition, based on the
hazard ratio and subgroup analysis, had a prognostic
advantage over the RCP criteria.12 Concordant to these
results, we found that the optimal CRM cutoff value in the
surgery-alone group, analyzed with the Akaike Information
Criterion, was the CAP.
Beside the CRM, lymph node metastasis associated
variables were important prognostic factors in this study;
lymph node ratio[0.2 was independent prognostic for both
2-year DFS and LRFS in the surgery-alone group and pN-
stage was the only prognostic factor for 2-year DFS in the
nCRT group. One meta-analysis, which underlined the
importance of lymph node metastasis, indicated that nodal
metastases appeared to negate the prognostic value of the
CRM.12 Moreover, the presence of lymph node metastases
and an involved CRM indicated a more advanced-staged
disease.26 Another prognostic factor in surgery-alone
patients was the tumor length, which is in correspondence
with previously published data.27
Pultrum et al. assessed the optimal CRM in surgically
treated patients using the area under the curve (AUC)
analysis on receiver operating curves (ROC, which does
not incorporate the time factor.2 A method that includes the
time factor is the more complex time-dependent ROC
method according to Heagerty et al.28 For our limited
explorative study, however, we prefer to use multivariate
Cox regression analysis and suggest validating the results
in a larger cohort.
CONCLUSIONS
This study showed that both definitions of a tumor-free
CRM (CAP[ 0 mm, RCP[ 1 mm) were not prognostic
for DFS in patients treated with nCRT. A free CRM
according the CAP definition was prognostic for 2-year
DFS in the surgery-alone group and an optimal CRM
cutoff between 0.0 and 0.2 and at 0.3 mm in the surgery-
alone and nCRT groups, respectively. These findings
should be validated in a large, prospective study.
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TABLE 4 Studies regarding prognostic value of the circumferential resection margin after neoadjuvant chemoradiotherapy
Study (year) Histology Stage Patients (n) nCRT (%) Outcome CRM definition P valuea
Thompson et al.23 AC, SCC cT1–4 240 124 (52 %) 5-year survival RCP NS
Chao et al.13 SCC ypT3 151 151 (100 %) LRFS RCP \0.05
DFS RCP \0.05
DSS RCP \0.05
Harvin et al.15 AC ypT3 160 160 (100 %) OS, DFS, LRFS CAP NS
OS, DFS, LRFS RCP NS
Reid et al.25 AC SCC cT1–4 269 42 (16 %) DFS RCP \0.01
OS RCP 0.05
O’Farrell et al.24 AC, SCC, others cT3 157 82 (52 %) OS RCP NS
OS CAP 0.02
Liu et al.14 SCC cT1–4 94 94 (100 %) OS RCP \0.01
SCC squamous cell carcinoma, AC adenocarcinoma, nCRT neoadjuvant chemoradiotherapy, cT clinical T stage, ypT pathologic T stage after
nCRT, DFS disease-free survival, LRFS local recurrence-free survival, DSS disease-specific survival, CRM circumferential resection margin,
CAP College of American Pathologists, RCP Royal College of Pathologists
a Multivariate analysis
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